3 May 2024

DILAPAN-S Gains Attention at BMFMS 2024: Two Posters Showcasing Real-World Data

DILAPAN-S, the non-pharmacological solution for cervical ripening, is gaining momentum within the medical community. At the British Maternal & Fetal Medicine Society (BMFMS) conference, held in Liverpool, UK, on April 25-26, 2024, valuable real-world data from UK hospitals were showcased in two informative posters.

For more details on the presented research, please refer to the provided link.

Research Highlights:

  • Real-World Efficacy and Safety: The first poster, “Multicentre National Retrospective Review of Outcomes Following Use of Dilapan-S for Cervical Priming,” demonstrated that Dilapan-S ensures efficacy and safety in real-world settings, including among high-risk patients. The findings confirm the absence of side effects and the versatility of Dilapan-S for labour induction.
  • Reduced Analgesic Needs: The second poster, “Analgesia Requirements During Induction of Labour with Synthetic Osmotic Dilator: Multicentre National Retrospective Review of Outcomes Following Use of Dilapan-S for Cervical Priming,” revealed that the use of Dilapan-S is associated with significantly low analgesic requirements. This reduction translates into a more comfortable experience for mothers.

These findings reinforce the potential of Dilapan-S as a first-line induction agent, incl. an out-patient regimen. The product offers a cost-effective solution with a high safety profile and success rate for both mothers and healthcare providers.

Any further information required?